Dr. Singer was awarded funds to lead the ABCSG (Austrian Breast Cancer Study Group) at the Medical University of Vienna to support the collaborative working group meetings of the BRCA-P [denosumab prevention] Steering Committee as well as preparatory work related to the creation of the study’s protocol.
The ABCSG group has hypothesized that denosumab, used to treat osteoporosis or breast cancer spread to bone, may be ‘repurposed’ as a prevention drug. BRCA-P is an international randomized controlled trial that will determine if denosumab prevents breast cancer. The protocol was approved and the trial, BRCA-P: An international randomised phase III study evaluating the RANK ligand inhibitor denosumab for the prevention of breast cancer in BRCA1 mutation carriers, began enrolling patients in 2018.